Table 1.
Clinical characteristics of patients. Age (W = 370, p = 0.542) and sex (χ2 = 0.937, p = 0.333) did not differ between MOG-IgG-seropositive patients and HCs
| HC | MOG-IgG-seropositive patients | |
|---|---|---|
| Subjects [N] | 28 | 24 |
| Number of eyes [N] | 56 | 38 |
| F/U [median years (min, max)] | 1.9 (0.8–3.3) | 1.9 (0.6–2.8) |
| Age [mean (SD)]; [range at baseline] | 43.12 (9.76); [11–68] | 40.66 (13.53); [15–68] |
| Sex [male (%)] | 6 (21.4) | 9 (37.5) |
| Clinical phenotypes (MOG-IgG-associated diseases) | – | ON (N = 7), NMOSD (N = 12), MS (N = 3), meningoencephalomyelitis (N = 2) |
| EDSS at baseline [median (IQR)] | – | 2.5 (2.0; 3.0) |
| Disease duration at baseline in years [median (IQR)] | – | 3.0(1.1; 8.8) |
| Eyes with a history of ON [EyeON+, N (%)] | – | 20 (52.6%) |
| Patients with a history of ON [N (%)] | – | 15 (62.5%) |
| Number of ON in EyeON+ [median (range)] | – | 2 (1–8) |
| Eyes without a history of ON [EyeON-, N (%)] | – | 18 (47.4%) |
| Time since ON [years; median (range)] | – | 2.2 (0.4–14.9) |
| Eyes with contralateral ON during F/U [N (%)] | – | 5 (13.2) |
| Treatment at baseline [N] | – | AZA [4], MTX [1], NAT [1], RIX [8], IVIG [1], PRED [2], NONE [7] |
Abbreviations: HC healthy controls, N number, SD standard deviation, F/U follow-up, AZA azathioprine, MTX methotrexate, NAT natalizumab, RIX rituximab, IVIG intravenous immunoglobulins, PRED prednisone, TOC tocilizumab, MMF mycophenolate mofetil, NONE no treatment